Louisiana State Employees Retirement System Buys Shares of 6,500 Medpace Holdings, Inc. (NASDAQ:MEDP)

Louisiana State Employees Retirement System bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 6,500 shares of the company’s stock, valued at approximately $1,992,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Cerity Partners LLC boosted its holdings in Medpace by 8.3% in the 4th quarter. Cerity Partners LLC now owns 2,463 shares of the company’s stock valued at $755,000 after purchasing an additional 189 shares during the last quarter. Custom Index Systems LLC acquired a new position in Medpace in the 4th quarter valued at about $484,000. Sequoia Financial Advisors LLC acquired a new position in Medpace in the 4th quarter valued at about $602,000. Miller Howard Investments Inc. NY boosted its holdings in Medpace by 1.3% in the 4th quarter. Miller Howard Investments Inc. NY now owns 3,075 shares of the company’s stock valued at $943,000 after purchasing an additional 39 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its holdings in Medpace by 248,773.8% in the 4th quarter. International Assets Investment Management LLC now owns 104,527 shares of the company’s stock valued at $32,041,000 after purchasing an additional 104,485 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Down 0.7 %

Shares of MEDP opened at $382.44 on Thursday. Medpace Holdings, Inc. has a fifty-two week low of $185.43 and a fifty-two week high of $419.42. The firm’s 50 day moving average price is $393.75 and its 200 day moving average price is $318.67. The company has a market cap of $11.85 billion, a P/E ratio of 43.07, a PEG ratio of 2.03 and a beta of 1.38.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 12th. The company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.24. Medpace had a net margin of 15.00% and a return on equity of 63.98%. The firm had revenue of $498.40 million for the quarter, compared to the consensus estimate of $498.72 million. During the same period in the prior year, the firm earned $2.12 EPS. The firm’s revenue for the quarter was up 26.5% on a year-over-year basis. Research analysts forecast that Medpace Holdings, Inc. will post 10.53 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Medpace Investors, Llc sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the sale, the insider now directly owns 5,539,947 shares of the company’s stock, valued at approximately $2,170,274,237.25. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Medpace news, CEO August J. Troendle sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $408.71, for a total transaction of $10,217,750.00. Following the completion of the transaction, the chief executive officer now owns 4,733,019 shares in the company, valued at approximately $1,934,432,195.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the transaction, the insider now owns 5,539,947 shares of the company’s stock, valued at approximately $2,170,274,237.25. The disclosure for this sale can be found here. Insiders have sold a total of 189,340 shares of company stock valued at $76,651,647 in the last ninety days. Company insiders own 20.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Medpace in a research note on Monday, March 18th. They issued a “hold” rating and a $395.00 price target on the stock. Robert W. Baird boosted their price target on shares of Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a research note on Wednesday, February 14th. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, March 23rd. Finally, UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and boosted their price target for the company from $282.00 to $452.00 in a research note on Thursday, February 15th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $382.00.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.